Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)
暂无分享，去创建一个
A. LaCasce | S. Tyekucheva | P. Armand | M. Davids | D. Fisher | C. Jacobson | S. Ng | Jennifer R. Brown | M. Weinstock | J. Arnason | B. Lampson | Jennifer L. Crombie | Austin I. Kim | S. Pazienza | Josie S. Montegaard | V. Patterson | J. Lowney